Mesa Laboratories Inc, a global leader in the design and manufacturing of life science tools and critical quality control solutions, announced its commitment to calculate and disclose scope 1 and 2 greenhouse gas emissions prior to the August 2024 Annual Meeting of Shareholders as part of its sustainability roadmap.
LAKEWOOD, Colo., Aug. 24, 2023 (GLOBE NEWSWIRE) -- Mesa Laboratories Inc (Nasdaq: MLAB; “Mesa” or the “Company”), a global leader in the design and manufacturing of life science tools and critical quality control solutions, today announced its commitment to calculate and disclose scope 1 and 2 greenhouse gas emissions prior to the August 2024 Annual Meeting of Shareholders as part of its sustainability roadmap. This commitment emphasizes Mesa’s longstanding commitment to corporate responsibility, including environmental initiatives.
“Company-wide, we address climate risks and opportunities through the lens of theMesa Way, which is a lean-based system for continuously improving,” said Gary Owens, CEO. “Our products and services benefit the lives of global communities, because the Mesa Way focuses first on protecting the patients that we serve and delivering for our customers in the broader healthcare sector. We accomplish these objectives by focusing on improving the efficiency of our operations and global facilities, through manufacturing process improvements, which may include initiatives that reduce waste and energy consumption.”
While Mesa has always tracked utility costs and usage, tracking scope 1 and scope 2 greenhouse gas emissions will provide a comprehensive, comparable, transparent view of the Company’s greenhouse gas emissions.
About Mesa Laboratories, Inc.
Mesa is a global leader in the design and manufacturing of life science tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare and medical device industries. Mesa offers products and services through four divisions (Sterilization and Disinfection Control, Biopharmaceutical Development, Clinical Genomics, and Calibration Solutions) to help our customers ensure product integrity, increase patient and worker safety, and improve the quality of life throughout the world.
CONTACT: Gary Owens; President and CEO, or John Sakys; CFO, both of Mesa Laboratories, Inc., +1-303-987-8000 For more information about the Company, please visit its website at www.mesalabs.com
